Regeneron Pharmaceuticals, Inc. · REGN · Next earnings

Regeneron Pharmaceuticals, Inc. reports Wednesday, Oct 28, 2026

REGN reports before market open with consensus EPS at $15.99 and revenue at $4.54B. Last quarter: Regeneron Q1 Beats on Revenue and EPS as Pipeline Milestones Accumulate

Reports Before market open38 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $15.99 Calendar consensus
Consensus revenue $4.54B Calendar consensus
Report date Oct 28, 2026 Wednesday, date estimated
Session Before market open 38 days away

Where REGN left off: FY2026 Q1

Full report

Regeneron Q1 Beats on Revenue and EPS as Pipeline Milestones Accumulate

EPS surprise +6.3% Reported $9.47 vs $8.91
Revenue surprise +3.6% Reported $3.61B vs $3.48B
Stock move -6.2% Event window
Subsequent drift -9.4% Up to 20 sessions

Management adjusted only the GAAP gross-margin range to 77-78%, down from the 83-84% introduced with full-year 2026 guidance in Q4 2025, citing a temporary manufacturing interruption at the Limerick, Ireland facility. The overall revenue and operating-expense outlook was maintained. Guidance sentiment remains 'maintained.'

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Temporary production interruption at the Limerick, Ireland facility could impact product availability and margins.
  • Regulatory timelines for the EYLEA HD prefilled syringe, garetosmab, and other late-stage assets remain uncertain.
  • Increasing competition in immunology (biosimilars for EYLEA, other IL-4/IL-13 agents) and oncology.
  • Pricing pressure from the Most-Favored-Nation agreement and the broader drug-pricing environment.
  • Dependence on the Sanofi collaboration repayment schedule.

Questions analysts left open

  • Life-cycle expansion opportunities for DUPIXENT within the Sanofi collaboration.
  • Timing of FDA decisions for the EYLEA HD prefilled syringe and garetosmab.
  • PFS vs OS endpoints for fianlimab in metastatic melanoma.
  • Infection risk associated with BCMA bispecifics in multiple myeloma.
  • Potential competition from tirzepatide and other GLP-1/GIP agents.

Ask FN2 about REGN next report

Transcript, numbers and history already loaded
What should I watch for in REGN's next earnings report?How did REGN guide last quarter, and is consensus above or below that?Give me the bull and bear case going into REGN earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the REGN recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent REGN quarters

All REGN earnings
-6.2%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.